A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer.

der Biessen DAJ, van; JA, Gietema; Jonge MJA, de; IME, Desar; Hollander MW, den; M, Dudley; M, Dunbar; R, Hetman; C, Serpenti; H, Xiong; RK, Mittapalli; KM, Timms; P, Ansell; CK, Ratajczak; SP, Shepherd; Herpen CML, van

doi:10.1007/s10637-017-0551-z

Public

A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer.

Shared by NobleBlocks on Jan 8, 2018 • 12:00 AM UTC

Authors:

van der Biessen DAJ

Gietema JA

de Jonge MJA

Abstract

Purpose This phase 1 study examined safety, pharmacokinetics (PK), and efficacy of the poly(ADP-ribose) polymerase (PARP) inhibitor ABT-767 in patients with advanced solid tumors and BRCA1/2 mutations or with high-grade serous ovarian, fallopian tube, or primary peritoneal cancer. Methods Patients r...

Subject

Ovarian cancer

Solid tumor

Brca

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!